Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Future Oncol. 2017 Sep;13(22):1911-1913. doi: 10.2217/fon-2017-0270. Epub 2017 Aug 22.

Authors

Burak Bilgin¹, Mehmet An Şendur¹, Mutlu Hızal¹, Muhammed Bülent Akıncı¹, Didem Şener Dede¹, Bulent Yalçın¹

Affiliation

¹ Yıldırım Beyazıt University, Faculty of Medicine, Department of Medical Oncology, 06800, Bilkent, Ankara, Turkey.

PMID: 28829190
DOI: 10.2217/fon-2017-0270

No abstract available

Keywords: abiraterone; androgen deprivation therapy; docetaxel; prostate cancer.

Publication types

Editorial